

Background information
The CBBM's new research building comprises 5,400 square meters of main floor space spread over four stories. The building, designed by the Stuttgart architectural company, hammeskrause, which is specialized in scientific buildings, is characterized by its clear, light-flooded design and high functionality to meet the interests of the researchers. Two roofed atriums on two stories ensure that also the laboratories situated in the interior are generously provided with daylight. The total surface area of the exterior glass is 2,800 square meters. Carbon-neutral heating with a cogeneration unit run on biogas inside the building provides heating. The cost of construction, financed by the federal and state governments, was 0.91 million euros, the initial fittings and furnishings costs excluding large equipment add up to 4.22 million euros. Construction began in March 2012. Construction was carried out by GMSH (Gebäudemanagement Schleswig-Holstein), whose managing director, Hans-Adolf Bilzhause, presented the key to the president of the university at the conclusion of the ceremonial event. Bilzhause said: "We utilized the tight building area to full capacity to construct here a new building with high functionali-ty and the greatest possible transparency. The result is a state-of-the-art interdisciplinary center with multidisciplinary research opportunities, from which science and research can benefit and that will light the way to the future for Schleswig-Holstein. We are building the center for biomedical research right next door. And already this year we will also begin construction of a new radionuclide laboratory. These three large new buildings will also completely transform the urban landscape of the University of Lübeck. The research groups working together in the CBBM, originated from a total of nine university institutes and clinics and the Schleswig-Holstein university hospital. Their international research includes 93 collaborations in more than 20 cities worldwide, including the University of California, Stanford University, Yale University, Harvard Medical School, Universidad de Chile, University of Cambridge, the Karolinska Institutet in Stockholm, the National Research Centre in Cairo, the University of Santo Tomas in Milan and the Westmead Clinical School in Sydney. As a part of the German Research Foundation (DFG), the CBBM research groups are participating in the special research areas of / Transregio 134 (Ingestive Behavior: Homeostasis and Reward") and 654 (Plasticity and Sleep) as well as the Research Training Group 1957 (Adipocyte - Brain - Crosstalk). At the European level, they are collaborating with the Marie Curie Initial Training Network "nEUROinflammation" and the seventh framework program for research, "Disorders of sexual development", as well as the German Center for Diabetes Research (DZD). The projects are supported by two Heisenberg professorships from the German Research Foundation and one Lichtenburg professorships from the Volkswagen Foundation. As technology platforms for research, the CBBM has at its disposal a 3-tesla magnetic resonance imaging device for neuronal imaging, a metabolic core unit for dual-energy X-ray absorptiometry, whole-body air displacement plethysmography and indirect calorimetry as well as a bioanalytical core facility for metabolomics and mass spectrometry and for the analysis of hormones.Contact
Peter Wiegand, Head of Communication and MarketingTel. +49 451 500 1789, mobile +49 151 22 66 38 00,
email: peter.wiegand@uni-luebeck.de

More News

Pacira BioSciences Acquires GQ Bio
HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...
Read more …
CrystalsFirst Scales Operations...
CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...
Read more …
Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT
medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...
Read more …